Wedbush Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Wedbush analyst maintained a Hold rating on Intellia Therapeutics today and set a price target of $7.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. In addition to Wedbush, Intellia Therapeutics also received a Hold from JonesTrading’s Debanjana Chatterjee in a report issued today. However, yesterday, Truist Financial reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).